title: Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
authors.forename: Eugenio
authors.initials: E
authors.lastname: Piro
authors.forename: Mariagrazia
authors.initials: M
authors.lastname: Kropp
authors.forename: Renato
authors.initials: R
authors.lastname: Cantaffa
authors.forename: Angelo Giuseppe
authors.initials: AG
authors.lastname: Lamberti
authors.forename: Guido
authors.initials: G
authors.lastname: Carillio
authors.forename: Stefano
authors.initials: S
authors.lastname: Molica
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000187:drug effects / Q000276:immunology / Q000469:parasitology / Q000473:pathology; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007558:Italy; D007893:Leishmania donovani / Q000187:drug effects / Q000302:isolation & purification; D007898:Leishmaniasis, Visceral / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000469:parasitology; D061988:Proteasome Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000981:Antiprotozoal Agents; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib